KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez Otero, Roman Hájek, Elisabetta Antonioli, Mark van Duin, Mattia D'Agostino, Joaquín Martínez-López, Elena M van Leeuwen-Segarceanu, Elena Zamagni, Niels W C J van de Donk, Katja C Weisel, Luděk Pour, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl

Nat Med 32(5) 1773-1782

PMID41942646
PMCIDPMC13190300
DOI10.1038/s41591-026-04282-0
发表日期2026-04-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:ROC 图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:森林图/亚组分析图;Extended Data Fig. 2:森林图/亚组分析图;另有 1 张未列出。
摘要

摘要

Induction and consolidation with a quadruplet therapy of a CD38-targeting monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug and dexamethasone are a standard-of-care treatment in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM) with the optimal drugs to be used still under debate. The ongoing, phase 3 EMN24 IsKia trial randomized 302 TE patients with NDMM aged ≤70 years 1:1 to isatuximab-carfilzomib-lenalidomide-dexamethasone (Isa-KRd) versus KRd pretransplant induction and post-transplant consolidation. The primary endpoint was the rate of measurable residual disease (MRD) negativity (sensitivity of 10-5 or better) by next-generation sequencing (NGS) after consolidation. Key secondary endpoints were the rates of NGS-MRD negativity after induction and progression-free survival (PFS). MRD negativity rates at higher sensitivity (10-6 or better) were exploratory. Post-consolidation MRD negativity was significantly higher with Isa-KRd versus KRd at the 10-5 (77% versus 67%; odds ratio (OR) 1.67, P = 0.049) and 10-6 (68% versus 48%; OR 2.36, P = 0.0004) sensitivities. Deep MRD responses were rapid (post-induction Isa-KRd versus KRd: 10-5 46% versus 27%, OR 2.32, P = 0.0007; 10-6 28% versus 14%, OR 2.44, P = 0.0029) and durable (1-year sustained 10-6 MRD negativity 52% versus 38%, OR 1.82, P = 0.012). At current follow-up, PFS data were immature. Grade 3-4 non-hematologic adverse events (AEs), treatment discontinuations and deaths due to AEs were similar in the two arms. Isa-KRd significantly improved NGS-MRD negativity in TE patients with NDMM, with a manageable safety profile. ClinicalTrials.gov registration: NCT04483739 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Trial profile. a In the KRd arm, one patient proceeded from induction to consolidation without mobilization and intensification due to patient’s preference. b Eight patients proceeded from mobilization to consolidation without intensification: 5 in the Isa-KRd arm (4 due to mobilization failure and 1 due to the patient’s preference) and 3 in the KRd arm (2 due to mobilization failure and 1 due to the patient’s preference).
非 KM Figure
Fig. 2Subgroup analysis of post-ASCT full-dose consolidation MRD negativity rates (assessed by NGS). a , 10 −5 cut-off. b , 10 −6 cut-off. Squares represent the odds ratios for Isa-KRd versus KRd overall and in subgroup variables from a logistic model adjusted for stratification factors. The square size is proportional to the subgroup size. Error bars correspond to 95% CIs. Two-sided Wald test P values for interaction between arms and subgroup variables are reported. No multiple-comparison adjustment was applied. 10 −5 , NGS at the sensitivity of 10 −5 ; 10 −6 , NGS at the sensitivity of 10 −6 ; MRD − , measurable residual disease-negative; No., number.
非 KM Figure
Fig. 3Subgroup analysis of 1-year sustained MRD negativity rates (assessed by NGS). a , 10 −5 cut-off. b , 10 −6 cut-off. Squares represent the odds ratios for Isa-KRd versus KRd overall and in subgroup variables from a logistic model adjusted for stratification factors. The square size is proportional to the subgroup size. Error bars correspond to 95% CIs. Two-sided Wald test P values for interaction between arms and subgroup variables are reported. No multiple-comparison adjustment was applied. sust., sustained.
非 KM Figure
Extended Data Fig. 1Subgroup analysis of post-induction MRD negativity rates (assessed by NGS). a , 10 −5 cut-off. b , 10 −6 cut-off. Squares represent the odds ratios for Isa-KRd vs. KRd overall and in subgroup variables from a logistic model adjusted for stratification factors. The square size is proportional to the subgroup size. Error bars correspond to 95% CIs. Two-sided Wald test P for interaction between arms and subgroup variables are reported. No multiple comparison adjustment was applied. Abbreviations . MRD, measurable disease negativity; NGS next-generation sequencing; Isa, isatuximab; K, carfilzomib; R, lenalidomide; d, dexamethasone; No., number; MRD − , measurable residual disease-negative; OR, odds ratio; CI, confidence interval; P , p-value; IMWG, International Myeloma Working Group; IMS, International Myeloma Society; HRCA, high-risk cytogenetic abnormalities; R-ISS, Revised International Staging System stage; R2-ISS, Second Revision of the International Staging System stage.
非 KM Figure
Extended Data Fig. 2Subgroup analysis of post-ASCT MRD negativity rates (assessed by NGS). a , 10 −5 cut-off. b , 10 −6 cut-off. Squares represent the odds ratios for Isa-KRd vs. KRd overall and in subgroup variables from a logistic model adjusted for stratification factors. The square size is proportional to the subgroup size. Error bars correspond to 95% CIs. Two-sided Wald test P for interaction between arms and subgroup variables are reported. No multiple comparison adjustment was applied. Abbreviations . ASCT, autologous stem-cell transplantation; MRD, measurable disease negativity; NGS next-generation sequencing; Isa, isatuximab; K, carfilzomib; R, lenalidomide; d, dexamethasone; No., number; MRD − , measurable residual disease-negative; OR, odds ratio; CI, confidence interval; P , p-value; IMWG, International Myeloma Working Group; IMS, International Myeloma Society; HRCA, high-risk cytogenetic abnormalities; R-ISS, Revised International Staging System stage; R2-ISS, Second Revision of the International Staging System stage.
非 KM Figure
Extended Data Fig. 3Trial design and MRD time points. Abbreviations . MRD, measurable residual disease; TE, transplant-eligible; NDMM, newly diagnosed multiple myeloma; FISH, fluorescence in situ hybridization; del, deletion; t, translocation; ISS, International Staging System stage; R, randomization; Isa, isatuximab; K, carfilzomib; R, lenalidomide; d, dexamethasone; IV, intravenous; dd, days; cc, cycles; PO, orally; Cy, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; MEL, melphalan; ASCT, autologous stem-cell transplantation.
非 KM Figure